The pharmacogenetics of asthma treatment

Current Allergy and Asthma Reports

Volumn 9, Issue 1, 2009, Pages 10-17

  Tantisira, Kelan ^a   Weiss, Scott ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ASTHMA; GENETICS; HUMAN; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 69149086152     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-009-0002-9     Document Type: Review

References (49)

1. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478. (Pubitemid 38580764)
2. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al.: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelu-kast/Beclomethasone Study Group. Ann Intern Med 1999, 130:487-495. (Pubitemid 29135801)
3. Szefier SJ, Martin RJ, King TS, et al.: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002, 109:410-418. (Pubitemid 34234189)
4. Drazen JM, Silverman EK, Lee TH: Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000, 56:1054-1070. (Pubitemid 32417168)
5. Tantisira KG, Lake S, Silverman ES, et al.: Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004, 13:1353-1359. (Pubitemid 38961642)
6. Lima JJ, Zhang S, Grant A, et al.: Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006, 173:379-385. (Pubitemid 43228324)
7. Enright PL, Lebowitz MD, Cockroft DW: Physiologic measures: pulmonary function tests. Asthma outcome. Am J Respir Crit Care Med 1994, 149: S9-S18; discussion S19-S20. (Pubitemid 24979662)
8. Brand PL, Duiverman EJ, Waalkens HJ, et al.: Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999, 54:103-107. (Pubitemid 29101351)
9. Frischer T, Meinert R, Urbanek R, Kuehr J: Variability of peak expiratory flow rate in children: short and long term reproducibility. Thorax 1995, 50:35-39.
10. National Heart, Lung, and Blood Institute: Highlights of the Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NIH Publications; 1997:50.
11. Raby BA, Weiss ST: Beta2-adrenergic receptor genetics. Curr Opin Mol Ther 2001, 3:554-566.
12. Osler W: Osler's Principles and Practice of Medicine, edn 14. New York: D. Appleton-Century Company; 1942.
13. Chung KF, O'Byrne P: Pharmacological agents used to treat asthma. In Asthma, vol 8. Edited by Chung KF, Fabbri LM. Sheffield, England: European Respiratory Society Journals; 2003:458.
14. Kobilka BK, Dixon RA, Frielle T, et al.: cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987, 84:46-50. (Pubitemid 17013575)
15. Reihsaus E, Innis M, MacIntyre N, Liggett SB: Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993, 8:334-339.
16. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP: An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet Genomics 2006, 16:705-711. (Pubitemid 44454864)
17. Martinez FD, Graves PE, Baldini M, et al.: Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997, 100:3184-3188. (Pubitemid 28022857)
18. Choudhry S, Ung N, Avila PC, et al.: Pharmacogenetic differences in response to albuterol between Puerto Rican and Mexican asthmatics. Am J Respir Crit Care Med 2005, 171: 563-570. (Pubitemid 40365410)
19. Silverman EK, Kwiatkowski DJ, Sylvia JS, et al.: Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 2003, 112:870-876. (Pubitemid 37412053)
20. Drysdale CM, McGraw DW, Stack CB, et al.: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000, 97:10483-10488.
21. Hawkins GA, Tantisira K, Meyers DA, et al.: Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006, 174:1101-1109. (Pubitemid 44772080)
22. Panebra A, Schwarb MR, Swift SM, et al.: Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 3'-UTR alter expression and agonist regulation. Am J Physiol Lung Cell Mol Physiol 2008, 294:L190-L195. (Pubitemid 351253356)
23. Poon AH, Tantisira KG, Litonjua AA, et al.: Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmaco-genet Genomics 2008, 18:373-382. (Pubitemid 351535938)
24. Tantisira KG, Small KM, Litonjua AA, et al.: Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between {beta}-agonist and corticosteroid pathways. Hum Mol Genet 2005, 14:1671-1677. (Pubitemid 40895519)
25. Litonjua AA, Lasky-Su J, Schneiter K, et al.: ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008, 178: 688-694.
26. Drazen JM, Israel E, Boushey HA, et al.: Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996, 335:841-847. (Pubitemid 26304065)
27. Israel E, Drazen JM, Liggett SB, et al.: Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001, 124:183-186. (Pubitemid 32304798)
28. Dishy V, Sofowora GG, Xie HG, et al.: The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001, 345:1030-1035.
29. Israel E, Chinchilli VM, Ford JG, et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004, 364:1505-1512. (Pubitemid 39410416)
30. Tattersfield AE, Hall IP: Are beta2-adrenoceptor polymorphisms important in asthma-an unravelling story. Lancet 2004, 364:1464-1466. (Pubitemid 39410401)
31. Israel E, Drazen JM, Liggett SB, et al.: The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000, 162:75-80. (Pubitemid 30469801)
32. Wechsler ME, Lehman E, Lazarus SC, et al.: Beta-adrener-gic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006, 173:519-526.
33. Palmer CN, Lipworth BJ, Lee S, et al.: Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006, 61:940-944. (Pubitemid 44787162)
34. Bleecker ER, Postma DS, Lawrance RM, et al.: Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007, 370:2118-2125. (Pubitemid 350296302)
35. Bleecker ER, Yancey SW, Baitinger LA, et al.: Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006, 118:809-816. (Pubitemid 44498754)
36. Bukstein DA, Bratton DL, Firriolo KM, et al.: Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromo-lyn: a randomized, open-label, crossover study. J Asthma 2003, 40:475-485. (Pubitemid 37175481)
37. Lima JJ: Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther 2007, 11:97-104. (Pubitemid 46572570)
38. Mougey EB, Feng H, Castro M, et al.: Montelukast plasma concentration associates with a common SNP in SLCO2B1. Clin Pharmacol Ther 2008, 83:S67.
39. In KH, Asano K, Beier D, et al.: Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997, 99:1130-1137. (Pubitemid 27123651)
40. Drazen JM, Yandava CN, Dube L, et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999, 22:168-170. (Pubitemid 29264811)
41. Telleria JJ, Blanco-Quiros A, Varillas D, et al.: ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008, 102:857-861.
42. Klotsman M, York TP, Pillai SG, et al.: Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007, 17:189-196. (Pubitemid 46668003)
43. Finotto S, Neurath MF, Glickman JN, et al.: Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002, 295:336-338. (Pubitemid 34074365)
44. Tantisira KG, Hwang ES, Raby BA, et al.: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004, 101:18099-18104. (Pubitemid 40054080)
45. Tantisira KG, Silverman ES, Mariani TJ, et al.: FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007, 120:1285-1291. (Pubitemid 350216603)
46. Klein RJ: Power analysis for genome-wide association studies. BMC Genet 2007, 8:58.
47. Van Steen K, McQueen MB, Herbert A, et al.: Genomic screening and replication using the same data set in family-based association testing. Nat Genet 2005, 37:683-691. (Pubitemid 41754884)
48. Hakonarson H, Bjornsdottir US, Halapi E, et al.: Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA 2005, 102:14789-14794. (Pubitemid 41457134)
49. Shu Y, Sheardown SA, Brown C, et al.: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007, 117:1422-1431. (Pubitemid 46718430)